Solara Active Pharma Sciences Ltd.
Snapshot View

1644.50 +17.05 ▲1.1%

30 July 2021, 04:00:00 P.M.
Volume: 3,720

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.solara.co.in
Financial Indicators
Market Cap 5,908.65 Cr.
Earnings per share (EPS) 61.62 Trailing Twelve Months Ending 2021-03
Price-Earning Ratio (PE) 26.69 Trailing Twelve Months Ending 2021-03
Industry PE 34.39 Trailing Twelve Months Ending 2021-03
Book Value / Share 442.12 Trailing Twelve Months Ending 2021-03
Price to Book Value 3.72 Calculated using Price: 1,644.50
Dividend Yield 0.18 Period Ending 2020-03
No. of Shares Subscribed 3.59 Cr. 35,929,767 Shares
FaceValue 10
Company Profile
Solara Active Pharma Sciences is a dynamic, entrepreneurial and customer-oriented API manufacturer. It has a legacy of over three decades and trace its origins to the API expertise of Strides Shasun Ltd. and the technical know-how of human API business from Sequent Scientific Ltd.

The company is poised to bridge the industry gap by delivering value-based products while maintaining focus on customer needs. It has hundreds of scientists working at its two R&D Centers and many API manufacturing facilities armed with global approvals and 2 dedicated R&D facilities. 

The company has a highly compliant manufacturing footprint spread over six large scale multi-product facilities. The company’s business is spread across several countries with extensive operations in the key markets of North America, Europe, Japan, South Korea and the Middle East and North Africa. 

Business area of the company

The company is a global, R&D focused, pureplay API company engaged in the manufacturing and development of APIs and offering Contract Manufacturing and Development Services for global companies. 

Products and services
  • Commercial and R&D products
  • Contract research and Manufacturing

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
+1.05%
1 Week
-3.73%
1 Month
-2.45%
3 Month
+7.96%
6 Month
+10.70%
1 Year
+150.61%
2 Year
+398.56%
5 Year
3 years 2018-03 2019-03 2020-03
Return on Equity (%) 0.04 7.36 12.48
Return on Capital Employed (%) 1.82 9.70 11.73
Return on Assets (%) 0.02 3.14 5.57

Balance Sheet View Details

Particulars 3 years 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Shh. Funds 764 956 1,086
Non Curr. Liab. 315 344 333
Curr. Liab. 738 656 730
Minority Int. 4 4 4
Equity & Liab. 1,821 1,960 2,153
Non Curr. Assets 1,214 1,312 1,481
Curr. Assets 608 648 672
Misc. Exp. not W/O
Total Assets 1,821 1,960 2,153

Profit Loss View Details

Particulars 3 years 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Net Sales 560 1,409 1,322
Other Income 2 12 28
Total Income 563 1,421 1,349
Total Expenditure -501 -1,197 -1,062
PBIDT 62 224 287
Interest -25 -82 -78
Depreciation -37 -84 -94
Taxation 0 2 0
Exceptional Items
PAT 0 59 115

Cash Flow View Details

Particulars 3 years 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Cash Fr. Operatn. 49 166 244
Cash Fr. Inv. -85 -116 -359
Cash Fr. Finan. 68 -23 95
Net Change 31 27 -20
Cash & Cash Eqvt 46 76 56

Shareholding Pattern View Details

9 Qtrs 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%)
Promoter 40.55 40.55 40.14 41.88 41.88 44.24 44.13 44.11 41.07
Public 59.45 59.45 59.86 58.12 58.12 55.76 55.87 55.89 58.93
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 6.85 6.85 0.00 0.00 51.12 0.00 17.09 16.42 8.86

Announcements View Details

Fri, 30 Jul 2021
Reg. 34 (1) Annual Report
Pursuant to Regulation 34 of SEBI (LODR) Regulations 2015 we enclose the Notice convening the 4th Annual General Meeting (AGM) of shareholders and Annual Report for the financial year 2020-21 which will be circulated to the shareholders through electronic mode for the AGM to be held on Wednesday August 25 2021 at 10.30 AM (IST) through video conference (VC).

The Notice and the annual report will also be made available on the Companys website at www.solara.co.in
Thu, 29 Jul 2021
Fixes Book Closure for Dividend & AGM
Solara Active Pharma Sciences Ltd has informed BSE that the Register of Members & Share Transfer Books of the Company will remain closed from Àugust 21 2021 to August 25 2021 (both days inclusive) for the purpose of Payment of Dividend & 4th Annual General Meeting (AGM) of the Company to be held on August 25 2021.
Thu, 29 Jul 2021
Announcement under Regulation 30 (LODR)-Newspaper Publication
Please find enclosed copies of the newspaper advertisement titled Annual General Meeting to be held over Video Conference Record Date and Final Dividend Information. The advertisements appeared in Business Standard and Lokmat (Marathi version).

Technical Scans View Details

Thu, 29 Jul 2021
Decreasing Relative Strength - Benchmark index Decreasing Relative Strength - Benchmark index
Decreasing Relative Strength - Sectoral index Decreasing Relative Strength - Sectoral index
Close Within 2 Year High Zone Close Within 2 Year High Zone
Both SRS And ARS Above Zero Both SRS And ARS Above Zero
Close Crossing Current Month Low Close Crossing Current Month Low

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 168,733.23 774.00 +10.1%
Divi's Laboratories Ltd. 128,656.69 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. 77,707.65 4,712.70 +0.9%
Cipla Ltd. 71,170.06 920.30 +4.3%
Cadila Healthcare Ltd. 58,547.84 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. 58,067.43 4,025.00 -0.3%
Aurobindo Pharma Ltd. 53,214.94 916.50 +0.9%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 58.11 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2021-03 64.84 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 44.73 4,712.70 +0.9%
Cipla Ltd. Consolidated 2021-03 29.59 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 27.44 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 386.19 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2021-03 9.98 916.50 +0.9%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 3.63 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2021-03 13.84 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 4.35 4,712.70 +0.9%
Cipla Ltd. Consolidated 2021-03 3.88 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 4.51 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.64 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2021-03 2.43 916.50 +0.9%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2020-03 0.00 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,712.70 +0.9%
Cipla Ltd. Consolidated 2020-03 0.18 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2020-03 0.33 916.50 +0.9%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2020-03 19.30 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,712.70 +0.9%
Cipla Ltd. Consolidated 2020-03 10.09 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.53 916.50 +0.9%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2020-03 25.36 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 4,712.70 +0.9%
Cipla Ltd. Consolidated 2020-03 12.53 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.80 916.50 +0.9%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2020-03 5,394.42 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,712.70 +0.9%
Cipla Ltd. Consolidated 2020-03 17,131.99 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2020-03 23,098.51 916.50 +0.9%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2020-03 1,376.54 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,712.70 +0.9%
Cipla Ltd. Consolidated 2020-03 1,546.98 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2020-03 2,844.69 916.50 +0.9%